MicroRNA-572 expression level in multiple sclerosis patients in Zanjan

Background and Objective: Multiple Sclerosis (MS) is a progressive neurodegenerative disease in the central nervous system. Many epidemiologic and genetic studies are revealed that both genetic and environment factors can influence the susceptibility of MS. Demyelination are caused disturbance in signal transduction in the length of nerve fibers. Investigation of substantial biomarkers could be important to early diagnosis of disease and its progress. Micro-RNAs (miRNAs) are regulatory agents for many genes, and some of them are detectable in body fluids including serum and plasma, which can be studied as biomarkers. Mir-572 is one of the most important micro-RNAs in the pathways of immune regulation. In this study, serum expression level Mir-572 in patients with MS has been investigated.Materials and Methods: miRNAs were extracted from blood plasma of 24 MS and 24 healthy subjects. After cDNA synthesis, the expression of mir-572 was evaluated by qPCR and using the mir-16 gene as a reference gene. Results by t-test were statistically analyzed.Results: A significant increase in the expression of mir-572 was observed in patients with MS.Conclusion: Due to the difference in plasma levels of miR-572 in MS patients, it may be used as a biomarker for screening and controlling the progression of the disease. Mir-572 is an inhibitor of NCAM protein mRNAs or CD56 whose presence in the nervous system can protect the nerve cells membrane and repairs the demyelinated cells. Therefore, suppression of this miRNA as a therapeutic target in MS disease might be consider.

Keywords:

mir-572 , MultipleSclerosis , NCAM , Biomarkers , qPCR.